Lin Liangguang, general manager of Uni Pharma (Photo/Ye Yijun)
【Investment Taiwan Network Reporter Ye Yijun/Report】Uni Pharma has a revenue of 137 million yuan in 2015 and an estimated revenue of 150 million yuan in 2016, and is expected to be publicly issued in the fourth quarter of this year!
Since 2014, Uni Pharma cancer detection reagent DR-70 has been approved by the Food and Drug Administration for marketing, and has been sold to domestic and foreign markets, and at present, in addition to being adopted by 11 medical centers in China, the sales in overseas markets have also spread good news, and long-term orders have been obtained in the European Union.
The company transferred from the United States AMDL technology, then in Taiwan to produce its own tumor marker DR-70 in vitro diagnostic reagents, in early May, DR-70 products exported 108 sets to the European Union, a single export broke through the 100 sets mark, in this regard, general manager Lin Liangguang also said that this year’s exports will continue to grow, is expected to reach 200 sets of single exports from July, the amount of more than 100,000 US dollars, is expected to grow to 700 sets of single exports in the fourth quarter!
Uni Pharma said that the export volume from 2017 to 2018 will have the opportunity to grow multiplely, and the main reason is that clinical trials have confirmed the value of the product for postoperative tracking of colorectal cancer, and EU countries have begun to include this product in insurance payment; In addition to the EU market, the company will also carry out a product inspection and registration program in the United States and Canada, with the goal of being approved for marketing in major countries around the world.
Huayu completed the quality inspection of DR-70 in August 2015 in Beijing, obtained the qualified report, and also conducted clinical trials in China, with a total number of patients will exceed 1,000, and will conduct 6 months of follow-up follow-up, and carry out multi-center clinical trials in three tertiary hospitals in two regions, General Manager Lin Liangguang hopes to complete the case by the end of 2016, and complete the clinical trial report in the first half of 2017 to be submitted to the China Food and Drug Administration for approval.
In addition, Uni Pharma has two agent products that obtained the second-level medical device license of the Ministry of Health and Welfare in December last year, and has begun to distribute goods to pharmacies, clinics and hospitals since May this year; Among them, the fecal occult blood test strip (EZ-Detect) can facilitate patients to test at home and reduce the time for patients to travel to and from the hospital, and another new medical device for minimally invasive electrocautery (RFA) surgery, which can be used for thyroid nodules and reduce the side effects of surgery, will be used in major hospitals from the second half of this year.
